NCT00438789Approved For Marketing不适用
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 1
研究概览
简要总结
The primary objective is to provide access to eculizumab for PNH patient pending commercial availability.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years old
- •Avoid conception; and
- •Willing and able to give written informed consent
排除标准
- •Active bacterial infection
- •Participation in any other drug trial
- •Pregnant breast feeding, or intending to conceive
- •Not vaccinated against N meningitidis
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsParoxysmal Nocturnal Hemoglobinuria (PNH)NCT03427060AKARI Therapeutics1
已完成
3 期
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With EculizumabHemoglobinuria, ParoxysmalNCT00122304Alexion Pharmaceuticals, Inc.85
招募中
不适用
Global PNH Patient RegistryParoxysmal Nocturnal HemoglobinuriaNCT05755867Aplastic Anemia and MDS International Foundation500
已完成
3 期
Eculizumab to Treat Paroxysmal Nocturnal HemoglobinuriaParoxysmal Hemoglobinuria, NocturnalNCT00130000National Heart, Lung, and Blood Institute (NHLBI)87
已完成
3 期
Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT03588026AKARI Therapeutics9